[PR Newswire] – Investors and other interested parties may access the live webcast of the meeting by visiting the Company’s website at www.jnj.com and clicking on the webcast icon. Caring for the world, one person at a time inspires and unites the people of Johnson & Johnson. Our approximately 128,700 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
Read more on this.
Johnson & Johnson (JNJ), valued at $267.87B, opened at $94.77.
During the trading session, JNJ traded between $94.00 to $95.20 and has traded between $78.77 and $95.99 over the past 12 months.
Priced at 16.05x this year’s forecasted earnings, JNJ shares are relatively expensive compared to the industry’s 8.08x forward p/e ratio.
And for those looking to make a return holding the stock, the company pays shareholders $2.64 per share annually in dividends, yielding 2.80%.
Consensus earnings for the current quarter by the 16 sell-side analysts covering the stock is an estimate of $1.48 per share, which would be $0.04 better than the year-ago quarter and a $0.00 sequential decrease. The full-year EPS estimate is $5.83, which would be a $0.31 better than last year.
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $18.00 Billion. If realized, that would be a 2.86% increase over the year-ago quarter.
In terms of ratings, Barclays downgraded JNJ from Overweight to Equal Weight (Jan 10, 2014). Previously, RBC Capital Mkts upgraded JNJ from Sector Perform to Outperform.
With the above information in mind, readers should note that the average price target is $101.08, which is 6.66% above where the stock opened this morning.
Summary (NYSE:JNJ) : Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and womens health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSONS, AVEENO, CLEAN & CLEAR, DABAO, JOHNSONS Adult, LUBRIDERM, NEUTROGENA, RoC, VENDÔME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; blood glucose monitoring and insulin delivery products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
Tag Helper ~ Stock Code: JNJ | Common Company name: Johnson & Johnson | Full Company name: Johnson & Johnson (NYSE:JNJ) .